Metacrine Reports Third-Quarter 2021 Results
November 11, 2021 08:00 ET
|
Metacrine, Inc.
SAN DIEGO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal and...
Inventiva publie ses informations financières du 3ème trimestre 2021
November 10, 2021 16:00 ET
|
INVENTIVA
Trésorerie et équivalents de trésorerie à 105,7 M€ au 30 septembre 2021 Chiffre d’affaires de 0,2 M€ sur les neuf premiers mois de 2021 Daix (France), Long Island City (New York, United States),...
Inventiva reports 2021 Third Quarter Financial Information
November 10, 2021 16:00 ET
|
INVENTIVA
Cash and cash equivalents at €105.7m as of September 30, 2021Revenues of €0.2m for the first nine months of 2021 Daix (France), Long Island City (New York, United States), November 10, 2021 –...
Metacrine Reports Topline Results for MET409 Phase 2a Combination Trial In Patients with Type 2 Diabetes and NASH
November 02, 2021 08:00 ET
|
Metacrine, Inc.
- Validates therapeutic benefit of combination approaches for a large segment of NASH patients- Demonstrates additive efficacy results and favorable tolerability profile SAN DIEGO, Nov. 02, 2021...
Inventiva annonce sa participation à plusieurs conférences investisseurs en novembre 2021
October 29, 2021 09:29 ET
|
INVENTIVA
Daix (France), Long Island City (New York, United States), le 29 novembre 2021 – Inventiva (Euronext Paris et Nasdaq : IVA), société biopharmaceutique spécialisée dans le développement clinique de...
Inventiva announces participation at several conferences in November 2021
October 29, 2021 09:29 ET
|
INVENTIVA
Daix (France), Long Island City (New York, United States), November 29, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral...
Inventiva annonce le design de LEGEND, un essai clinique de Phase IIa combinant lanifibranor et empagliflozine, un inhibiteur du SGLT2, chez des patients atteints de la NASH et de diabète de type 2
October 27, 2021 16:00 ET
|
INVENTIVA
L’essai clinique LEGEND est un essai de Phase IIa de preuve de concept visant à évaluer la sécurité et l'efficacité de lanifibranor en combinaison avec empagliflozine, un inhibiteur du co-transporteur...
Inventiva announces the design of LEGEND, a Phase IIa combination trial with lanifibranor and SGLT2 inhibitor empagliflozin in patients with NASH and type 2 diabetes
October 27, 2021 16:00 ET
|
INVENTIVA
The LEGEND trial is a proof-of-concept Phase IIa clinical trial to evaluate the safety and efficacy of lanifibranor in combination with the sodium-glucose cotransporter 2 (SGLT2) inhibitor...
Global Liver Institute Applauds Congresswoman Velázquez and Senator Duckworth for Bold Action on Liver Cancer
October 22, 2021 10:12 ET
|
Global Liver Institute
Washington, DC, USA, Oct. 22, 2021 (GLOBE NEWSWIRE) -- (Washington, DC, Friday, October 22, 2021)—Global Liver Institute (GLI) CEO and President, Donna R. Cryer, JD, yesterday applauded the actions...
Metacrine Reports Interim Results for MET642 Phase 2a Trial in Patients with NASH and Announces a Strategic Re-Prioritization of Its Clinical Development Programs
October 21, 2021 16:01 ET
|
Metacrine, Inc.
SAN DIEGO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and...